The Cryptococcal Meningitis drugs in development market research report provides comprehensive information on the therapeutics under development for Cryptococcal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cryptococcal Meningitis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cryptococcal Meningitis and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Cryptococcal Meningitis by eight companies/universities/institutes. The top development phase for Cryptococcal Meningitis is preclinical with three drugs in that stage. The Cryptococcal Meningitis pipeline has five drugs in development by companies and three by universities/ institutes. Some of the companies in the Cryptococcal Meningitis pipeline products market are: Mycovia Pharmaceuticals, Pfizer and Second Military Medical University.

The key targets in the Cryptococcal Meningitis pipeline products market include GPI Anchored Wall Transfer Protein 1 (PfGWT1 or EC 2.3.), Thymidylate Synthase (TYMS or EC, and Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC

The key mechanisms of action in the Cryptococcal Meningitis pipeline product include Thymidylate Synthase (TYMS or EC Inhibitor with two drugs in Phase I. The Cryptococcal Meningitis pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Cryptococcal Meningitis pipeline products market including Small Molecule, and Vaccine.

Cryptococcal Meningitis overview

Cryptococcal meningitis is a fungal infection of the meninges, the tissues that cover the brain and spinal cord. The infection is caused by the fungus Cryptococcus, which spreads from the lungs to the brain. Symptoms include headache, fever, confusion, cough, achy chest, rash. Definitive diagnosis of cryptococcal meningitis is made by culture from the CSF. Antifungal agents for the treatment of cryptococcal meningitis are intravenous amphotericin B deoxycholate and its lipid formulations, oral flucytosine, and oral fluconazole.

For a complete picture of Cryptococcal Meningitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.